Want to see AZTR full AI Analyst Report?
AZTR Stock Chart & Stats
$0.13
<$0.01(1.03%)
At close: 4:00 PM EDT
$0.13
<$0.01(1.03%)
Day’s Range― - ―
52-Week Range$0.10 - $1.40
Previous Close$0.13
Volume406.85K
Average Volume (3M)169.78K
Market Cap
$7.59M
Enterprise Value-$3.08
Total Cash (Recent Filing)$6.73M
Total Debt (Recent Filing)$410.05K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Nov 17, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding60,603,740
10 Day Avg. Volume152,326
30 Day Avg. Volume169,784
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Improved CapitalizationLow debt and repaired capitalization give Azitra more financial flexibility than its loss profile alone suggests. This can support continued clinical and platform investment, although ongoing losses still limit the strength of the balance-sheet improvement.
Broader Platform And Commercial ApplicationsExpansion beyond a single clinical indication creates multiple potential revenue pathways across cosmetics, research tools, and dermatology therapeutics. Diversification may improve partnering options and reduce dependence on one drug program over the next several years.
NYSE American Compliance RestoredRestored listing compliance removes an immediate structural threat to market access and supports the company’s ability to finance and develop its pipeline. Enhanced monitoring for 12 months remains, but resolving the deficiencies improves governance and operating continuity.
Bears Say
Pre-Revenue And Persistent LossesAzitra has not established recurring commercial revenue and continues to absorb substantial annual losses. Without validated product sales, future value depends heavily on clinical progress, partnerships, or additional financing rather than an internally funded operating model.
Severe And Ongoing Cash BurnPersistent negative operating and free cash flow indicates that Azitra cannot currently fund development from operations. Continued trials and product work therefore create recurring financing needs, increasing execution risk if capital markets or partner funding do not remain available.
Dilution And Pipeline Prioritization RiskThe large increase in authorized shares provides financing flexibility but creates substantial potential dilution for existing holders. Pausing ATR-12 also shows capital constraints are affecting pipeline breadth, which may reduce scientific and commercial upside if resources remain limited.
Azitra Inc News
AZTR FAQ
What was Azitra Inc’s price range in the past 12 months?
Azitra Inc lowest stock price was $0.10 and its highest was $1.40 in the past 12 months.
What is Azitra Inc’s market cap?
Azitra Inc’s market cap is $7.59M.
When is Azitra Inc’s upcoming earnings report date?
Azitra Inc’s upcoming earnings report date is Nov 17, 2026 which is in 88 days.
How were Azitra Inc’s earnings last quarter?
Azitra Inc released its earnings results on Aug 12, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.055.
Is Azitra Inc overvalued?
According to Wall Street analysts Azitra Inc’s price is currently Overvalued.
Does Azitra Inc pay dividends?
Azitra Inc does not currently pay dividends.
What is Azitra Inc’s EPS estimate?
Azitra Inc’s EPS estimate is -0.04.
How many shares outstanding does Azitra Inc have?
Azitra Inc has 60,603,740 shares outstanding.
What happened to Azitra Inc’s price movement after its last earnings report?
Azitra Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went up 3.704%.
Which hedge fund is a major shareholder of Azitra Inc?
Currently, no hedge funds are holding shares in AZTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Azitra Inc
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Technical Analysis
Ownership Overview
27.62% Insiders
0.47% Mutual Funds
69.91% Other Institutional Investors
1.99% Public Companies and
Individual Investors